SETOLAS Holdings, inc. concluded a partial assignment agreement with Kagawa university regarding rare sugar pharmaceutical patents which Kagawa Univ. had developed and owned. Now Kagawa Univ. and SETOLAS have jointly owned those patents, and have steadily obtained the patent rights in Japan and some other countries.
Magmitt Pharmaceutical Co., Ltd., which is one of SETOLAS HD’s subsidiary, aims to develop its new pharmaceutical business for anticancer drug etc. with taking three advantage of Kagawa Univ.’s research achievements, Magmitt’s technique and those patent rights.
